1. Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, Hambraeus J, Axelsson M, Nimer FA, Sundström P, Gunnarsson M, Johansson R, Mellergård J, Rosenstein I, Ayad A, Sjöblom I, Risedal A, de Flon P, Gilland E, Lindeberg J, Shawket F, Piehl F, Lycke J. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022 Aug;21(8):693-703.

2. Spelman T, Forsberg L, McKay K, Glaser A, Hillert J. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. Mult Scler. 2022 Jun;28(7):1051-1059.

3. Manouchehrinia A, Kingwell E, Zhu F, Tremlett H, Hillert J, Ramanujam R. A multiple sclerosis disease progression measure based on cumulative disability. Mult Scler. 2021 Oct;27(12):1875-1883.

4. Landtblom AM, Berntsson SG, Boström I, Iacobaeus E. Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol Scand. 2021 Sep;144(3):229-235.

5. Hedström AK, Hillert J, Brenner N, Butt J, Waterboer T, Strid P, Kockum I, Olsson T, Alfredsson L. DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):717-722.  

6. Stenberg E, Forsberg L, Hedström A, Hillert J, Näslund E. Bariatric and metabolic surgery in patients with morbid obesity and multiple sclerosis - a nationwide, matched cohort study. Surg Obes Relat Dis. 2021 Jun;17(6):1108-1114.

7. Kågström S, Fält A, Berglund A, Piehl F, Olsson T, Lycke J. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. Mult Scler Relat Disord. 2021 May;50:102842.

8. McKay KA, Friberg E, Razaz N, Alexanderson K, Hillert J. Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2021 Apr 1;78(4):478-482.

9. Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde R, Stawiarz L, Manouchehrinia A, Spelman T. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Front Neurol. 2021 Mar 17;12:647811.

10. Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021 Mar 16;96(11):e1574-e1584. 

1. Weisel K, Wadlund AO, Gungor G, Dergarabetian E, Pacheco C, Masurkar N, Rodriguez-Otero P. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy. Eur J Haematol. 2022 Oct;109(4):388-397.

2. E. Manna, K. Kikuchi , H. Chalubert , I. Amri, P. Medina. BRAF mutation testing and results among French patients with solid tumours. Poster presented at ESMO 2020.

3. Bassila L, Medina P, Chalubert H. Trends in anti-emetic drug use in hematology-oncology based on Cancerology data in France. Poster presented at ISPOR US 2020.

4. Chabernaud H, Descoins S, Flinois A, Real-world studies in Onco-hematology: which parameter should be used to measure the efficacy of treatments. Poster presented at ISPOR EU 2019.

5. Medina P, Chalubert H, Pezic N, Wiegand J, Brihaye H, Spitzer M. PCN147 Epidemiologic burden of pulmonary metastasis in France. Value in Health. 2019 May 1;22:S84.

6. Colomer R, Hall P, Szkultecka-Debek M, Bondi RC, Flinois A, Auziere S, Le Cléac'h JY. Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC. Breast Cancer Res Treat. 2018 Feb;168(1):197-205. 

7. Klein AB, Wang H, Shire N, Chalubert H, Alessandrini ER, Descoins S, Medina P. Treatment Patterns In Head & Neck Squamous Cell Cancer In France: Artiste Study on Cancerology Patient Charts. Value in Health. 2017 Oct 1;20(9):A419.

8. Chabernaud H, Bonnelye G, Flinois A, French physician sensitivity to and consideration of the costs of cancer treatment. Poster presented at ISPOR EU 2015.

9. Flinois A, Bonnelye G, Chabernaud H, Evolution of the number of patients treated for metastatic cancer between 2003 and 2013 in France. Poster presented at ISPOR EU 2015.

1. Terauchi M, Ideno Y, Hayashi K. Effect of shift work on excessive daytime sleepiness in female nurses: results from the Japan Nurses' Health Study. Ind Health. 2024 Jul 24;62(4):252-258.

2. Chung HF, Dobson AJ, Hayashi K, Hardy R, Kuh D, Anderson DJ, van der Schouw YT, Greenwood DC, Cade JE, Demakakos P, Brunner EJ, Eastwood SV, Sandin S, Weiderpass E, Mishra GD. Ethnic Differences in the Association Between Age at Natural Menopause and Risk of Type 2 Diabetes Among Postmenopausal Women: A Pooled Analysis of Individual Data From 13 Cohort Studies. Diabetes Care. 2023 Nov 1;46(11):2024-2034.

3. Yasui T, Ideno Y, Nagai K, Hayashi K. Characteristics of HRT users in Japan: Evidence from the Japan Nurses’ Health Study. Maturitas. 2023 Jul;173:1-6.

4. Otsuka E, Miyazaki Y,  Ideno Y, Nagai K, Kobayashi A, Kishi M, Lee JS, Hayashi K. Validity of a 98-item Food Frequency Questionnaire for the Japan Nurses’ Health Study. The Kitakanto Medical Journal. 2023;73(4):277-283. Medical*Online

5.  Liang C, Chung HF, Dobson AJ, Hayashi K, van der Schouw YT, Kuh D, Hardy R, Derby CA, El Khoudary SR, Janssen I, Sandin S, Weiderpass E, Mishra GD. Infertility, recurrent pregnancy loss, and risk of stroke: pooled analysis of individual patient data of 618 851 women. BMJ. 2022 Jun 22;377:e070603.

6. Hayashi K, Ideno Y, Nagai K, Lee JS, Yasui T, Kurabayashi T, Takamatsu K. Complaints of reduced cognitive functioning during perimenopause: a cross-sectional analysis of the Japan Nurses’ Health Study. Womens Midlife Health. 2022 Jun 5;8(1):6.

7. Yasui T, Ideno Y, Shinozaki H, Kitahara Y, Nagai K, Hayashi K. Prevalence of the Use of Oral Contraceptives and Hormone Replacement Therapy in Japan: The Japan Nurses' Health Study. J Epidemiol. 2022 Mar 5;32(3):117-124.

8. Katanoda K, Ideno Y, Maruoka N, Nagai K, Tsukada Y, Matsuki M, Higashi T, Hayashi K. Validation of Identifying Cancer Diagnosis Based on Self-Reported Information in the Japan Nurses' Health Study. Asian Pac J Cancer Prev. 2022 Feb 1;23(2):651-657.

9. Kishi M, Ideno Y, Nagai K, Lee JS, Suzuki S, Hayashi K. Use of Dietary Supplements among Japanese Female Nursing Professionals. J Nutr Sci Vitaminol (Tokyo). 2022;68(3):213-220.

10. Nagai K, Homma Y, Ideno Y, Hayashi K. Prevalence and factors associated with overactive bladder and stress urinary incontinence in the Japan Nurses' Health Study. Menopause. 2021 Dec 13;29(2):129-136.

https://research.ssri.co.jp/pmap/pastdata

https://research.ssri.co.jp/pmap/pastdata

1. Nozawa K, Matsuyama S, Higa S, Yamamoto Y, Asami Y. Physician consultation rates and characteristics among workers with chronic pain or headache who participated in a behavioural change program: a retrospective database analysis using real-world healthcare data. BMJ Open. 2022 Nov 10;12(11):e056846.

2. Higa S, Nozawa K, Karasawa Y, Shirai C, Matsuyama S, Yamamoto Y, Laurent T, Asami Y. The Use of a Network Analysis to Identify Associations and Temporal Patterns Among Non-communicable Diseases in Japan Based on a Large Medical Claims Database. Drugs Real World Outcomes. 2022 Sep;9(3):463-476.

3. Shirai C, Matsuoka N, Nakazawa T. Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: A retrospective non-interventional cohort study. BMC ophthalmology. 2021 Dec;21(1):1-2.

4. Osawa I, Goto T, Asami Y, Itoh N, Kaga Y, Yamamoto Y, Tsugawa Y. Physician visits and medication prescriptions for major chronic diseases during the COVID-19 pandemic in Japan: retrospective cohort study. BMJ open. 2021 Jul 1;11(7):e050938.

5. Nozawa K, Higa S, Ii Y, Yamamoto Y, Asami Y. Antidyslipidemic Drug Prescriptions and Lipid Control Status After Unfavorable Annual Health Checkup Results: A Retrospective Cohort Study Using a Health Insurance Database. Drugs-real world outcomes. 2021 Jun;8(2):227-40.

6. Higa S, Ii Y, Nozawa K, Yamamoto Y, Ohwaki K, Asami Y. Relationship of annual health checkups with the subject’s subsequent behavior of cardiovascular risk management in a real-world setting in Japan: a retrospective cohort study on changes in antihypertensive drug prescription and blood pressure from 2015 to 2017. Drugs-real world outcomes. 2021 Jun;8(2):215-25.

7. Osawa I, Goto T, Yamamoto Y, Tsugawa Y. Machine-learning-based prediction models for high-need high-cost patients using nationwide clinical and claims data. NPJ digital medicine. 2020 Nov 11;3(1):1-9.

8. Yuasa A, Murata T, Imai K, Yamamoto Y, Fujimoto Y. Treatment procedures and associated medical costs of methicillin-resistant Staphylococcus aureus infection in Japan: a retrospective analysis using a database of Japanese employment-based health insurance. SAGE open medicine. 2019 Aug;7:2050312119871181.

9. Higa S, Yoshida M, Shima D, Ii Y, Kitazaki S, Yamamoto Y, Fujimoto Y. A Retrospective, Cross-Sectional Study on the Prevalence of Hyperuricemia Using a Japanese Healthcare Database. Arch Rheumatol. 2019 Apr 22;35(1):41-51.

10. Hirano Y, Asami Y, Kuribayashi K, Kitazaki S, Yamamoto Y, Fujimoto Y. Possibility of database research as a means of pharmacovigilance in Japan based on a comparison with sertraline postmarketing surveillance. Value in health regional issues. 2018 May 1;15:1-5.